Truncating the gp41 cytoplasmic tail of simian immunodeficiency virus decreases sensitivity to neutralizing antibodies without increasing the envelope content of virions

Journal of Virology

Volumn 92, Issue 3, 2018, Pages

  White, Ellen ^a   Wu, Fan ^a   Chertova, Elena ^b   Bess, Julian ^b   Roser, James D ^b   Lifson, Jeffrey D ^b   Hirsch, Vanessa M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Macaques; Neutralizing antibodies; Simian immunodeficiency virus; Viral envelope

Indexed keywords

GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; MEMBRANE PROTEIN; SIV ENVELOPE PROTEIN GP41; VIRAL PROTEIN; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC50; MOLECULAR CLONING; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MODIFICATION; RHESUS MONKEY; SEQUENCE HOMOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; STOP CODON; VIRION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; ANIMAL; CELL LINE; ENVELOPE GENE; GENETICS; IMMUNOLOGY; PHYSIOLOGY; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CODON, TERMINATOR; GENES, ENV; HUMANS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; RETROVIRIDAE PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 85040673497     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01688-17     Document Type: Article

References (40)

1. Tedbury PR, Freed EO. 2015. The cytoplasmic tail of retroviral envelope glycoproteins. Prog Mol Biol Transl Sci 129:253-284. https://doi.org/10 .1016/bs.pmbts.2014.10.009
2. Postler TS, Desrosiers RC. 2012. The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol 87:2-15. https://doi.org/10 .1128/JVI.02053-12
3. Johnston PB, Dubay JW, Hunter E. 1993. Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 67: 3077-3086
4. Zingler K, Littman DR. 1993. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity. J Virol 67:2824-2831
5. Manrique JM, Celma CC, Affranchino JL, Hunter E, Gonzalez SA. 2001. Small variations in the length of the cytoplasmic domain of the simian immunodeficiency virus transmembrane protein drastically affect envelope incorporation and virus entry. AIDS Res Hum Retroviruses 17: 1615-1624. https://doi.org/10.1089/088922201753342022
6. Yuste E, Reeves JD, Doms RW, Desrosiers RC. 2004. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78:6775-6785. https:// doi.org/10.1128/JVI.78.13.6775-6785.2004
7. Yuste E, Johnson W, Pavlakis GN, Desrosiers RC. 2005. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol 79:12455-12463. https://doi.org/10.1128/JVI.79.19 .12455-12463.2005
8. Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP. 2015. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol 89:3380-3395. https://doi.org/10.1128/JVI.03473-14
9. Klasse PJ, Depetris RS, Pejchal R, Julien J-P, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP. 2013. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 87: 9873-9885. https://doi.org/10.1128/JVI.01226-13
10. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien J-P, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. 2015. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349:aac4223. https://doi.org/10.1126/science.aac4223
11. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220. https://doi.org/10.1056/NEJMoa0908492
12. Chertova E, Bess JW, Jr, Crise BJ, Sowder IR, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76:5315-5325. https://doi.org/10 .1128/JVI.76.11.5315-5325.2002
13. Zhu P, Chertova E, Bess J, Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100:15812-15817. https://doi.org/10.1073/pnas.2634931100
14. Zhu P, Liu J, Bess J, Jr, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852. https://doi.org/10.1038/ nature04817
15. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. 2006. Cryoelectron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2:e83. https://doi.org/10.1371/journal.ppat .0020083
16. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 6:e1001249. https://doi.org/10.1371/journal.ppat.1001249
17. White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, Bess JW, Lifson JD, Milne JL, Subramaniam S. 2011. Threedimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol 85:12114-12123. https://doi .org/10.1128/JVI.05297-11
18. Hu G, Liu J, Roux KH, Taylor KA. 2017. Structure of simian immunodeficiency virus envelope spikes bound with CD4 and monoclonal antibody 36D5. J Virol 91:e00134-17. https://doi.org/10.1128/JVI.00134-17
19. Sougrat R, Bartesaghi A, Lifson JD, Bennett AE, Bess JW, Zabransky DJ, Subramaniam S. 2007. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog 3:e63. https://doi.org/10.1371/journal.ppat.0030063
20. Chen J, Kovacs JM, Peng H, Rits-Volloch S, Lu J, Park D, Zablowsky E, Seaman MS, Chen B. 2015. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349:191-195. https://doi.org/10.1126/science.aaa9804
21. Lopker M, Easlick J, Sterrett S, Decker JM, Barbian H, Learn G, Keele BF, Robinson JE, Li H, Hahn BH, Shaw GM, Bar KJ. 2013. Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87:5477-5492. https://doi.org/10.1128/JVI.03419-12
22. Wu F, Ourmanov I, Kuwata T, Goeken R, Brown CR, Buckler-White A, Iyengar R, Plishka R, Aoki ST, Hirsch VM. 2012. Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J Virol 86:8835-8847. https://doi.org/10 .1128/JVI.00923-12
23. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439-1452. https://doi.org/10.1128/JVI.02108-09
24. Montefiori DC. 2004. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12:Unit 12.11. https://doi.org/10.1002/0471142735.im1211s64
25. Hirsch VM, Edmondson P, Murphey-Corb M, Arbeille B, Johnson PR, Mullins JI. 1989. SIV adaptation to human cells. Nature 341:573-574. https://doi.org/10.1038/341573a0
26. Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O'Dell S, Lusvarghi S, Bewley CA, Li H, Shaw GM, Sheng Z, Shapiro L, Wyatt R, Kwong PD, Mascola JR, Roederer M. 2016. Targeted isolation of antibodies directed against major sites of SIV Env vulnerability. PLoS Pathog 12: e1005537. https://doi.org/10.1371/journal.ppat.1005537
27. Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR. 2005. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339:226-238. https://doi.org/10.1016/j.virol.2005.06.003
28. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Sowder RC, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE. 2006. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80:9039-9052. https://doi.org/ 10.1128/JVI.01013-06
29. Kodama T, Wooley DP, Naidu YM, Kestler HW, Daniel MD, Li Y, Desrosiers RC. 1989. Significance of premature stop codons in Env of simian immunodeficiency virus. J Virol 63:4709-4714
30. Vzorov AN, Gernert KM, Compans RW. 2005. Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. Virology 332:89-101. https://doi.org/10.1016/j.virol.2004.10 .044
31. Bonavia A, Bullock BT, Gisselman KM, Margulies BJ, Clements JE. 2005. A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway. Virology 341:12-23. https://doi.org/10.1016/j.virol.2005.07.001
32. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, Watry DD, Fox HS, Desrosiers RC, Doms RW. 2002. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76: 2595-2605. https://doi.org/10.1128/JVI.76.6.2595-2605.2002
33. Kuwata T, Takaki K, Enomoto I, Kazuhisa Y, Matsushita S. 2013. Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Front Microbiol 4:117. https://doi.org/10.3389/fmicb.2013.00117
34. Chakrabarti L, Guyader M, Alizon M, Daniel MD, Desrosiers RC, Tiollais P, Sonigo P. 1987. Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature 328:543-547. https://doi.org/10.1038/328543a0
35. Vzorov AN, Compans RW. 1996. Assembly and release of SIV Env proteins with full-length or truncated cytoplasmic domains. Virology 221: 22-33. https://doi.org/10.1006/viro.1996.0349
36. Vzorov AN, Compans RW. 2000. Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization. J Virol 74:8219-8225. https://doi.org/10.1128/JVI.74.18.8219-8225.2000
37. Spies CP, Ritter GD, Jr, Mulligan MJ, Compans RW. 1994. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain. J Virol 68:585-591
38. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. https://doi.org/ 10.1128/AAC.46.6.1896-1905.2002
39. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497. https://doi.org/10.1093/ oxfordjournals.aje.a118408
40. Ourmanov I, Kuwata T, Goeken R, Goldstein S, Iyengar R, Buckler-White A, Lafont B, Hirsch VM. 2009. Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody. J Virol 83:5388-5400. https://doi.org/10.1128/JVI.02598-08